CORRECTED QT INTERVAL EFFECTS OF TRASTUZUMAB EMTANSINE (T-DM1) IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER AND THE SAFETY AND TOLERABILITY OF COMBINED T-DM1 AND PERTUZUMAB IN PATIENTS WITH EARLY DISEASE PROGRESSION: